Teva Pharmaceuticals
TEVA
688 hedge funds and large institutions have $18.6B invested in Teva Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 77 funds opening new positions, 257 increasing their positions, 256 reducing their positions, and 113 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 257 | Existing positions reduced: 256
2.09% less ownership
Funds ownership: 54.59% → 52.5% (-2.1%)
7% less funds holding
Funds holding: 739 → 688 (-51)
15% less capital invested
Capital invested by funds: $21.9B → $18.6B (-$3.25B)
25% less funds holding in top 10
Funds holding in top 10: 28 → 21 (-7)
32% less first-time investments, than exits
New positions opened: 77 | Existing positions closed: 113
50% less call options, than puts
Call options by funds: $321M | Put options by funds: $649M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$897M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$774M |
| 3 |
NC
Northern Cross
Boston,
Massachusetts
|
+$533M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$266M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$198M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$897M |
| 2 |
Lazard Asset Management
New York
|
-$346M |
| 3 |
PC
Paulson & Co
New York
|
-$168M |
| 4 |
Janus Henderson Group
London,
|
-$144M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$144M |
TEVA Hedge Fund Activity: Q1 2017 in Review
688 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q1 2017, worth a combined $18.6B — down 15% from $21.9B a quarter earlier.
Sellers outnumbered buyers: 113 funds closed out of TEVA and 77 opened new positions — a net loss of 36 holders — while 256 trimmed existing stakes and 257 added.
The largest buyer was BlackRock, adding an estimated $897M. The largest seller was Fidelity Investments, cutting an estimated $897M.
- 688 institutional investors held Teva Pharmaceuticals (TEVA) as of Q1 2017, down from 739 in Q4 2016.
- Funds reported $18.6B of Teva Pharmaceuticals stock for Q1 2017, down 15% quarter-over-quarter.
- 77 funds opened new Teva Pharmaceuticals positions in Q1 2017 and 113 closed out, a net change of -36 holders.
- The largest Teva Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $897M added.
- The largest Teva Pharmaceuticals seller in Q1 2017 was Fidelity Investments, an estimated $897M sold.
Based on aggregated 13F filings for Q1 2017.